Background and Purpose-Although preclinical studies have shown inflammation to mediate perihematomal edema (PHE) after intracerebral hemorrhage, clinical data are lacking. Leukocyte count, often used to gauge serum inflammation, has been correlated with poor outcome but its relationship with PHE remains unknown. Our aim was to test the hypothesis that leukocyte count is associated with PHE growth. Methods-We included patients with intracerebral hemorrhage admitted to a tertiary-care stroke center between 2011 and 2015. The primary outcome was absolute PHE growth during 24 hours, calculated using semiautomated planimetry. Linear regression models were constructed to study the relationship between absolute and differential leukocyte counts (monocyte count and neutrophil-lymphocyte ratio) and 24-hour PHE growth. Results-A total of 153 patients were included. Median hematoma and PHE volumes at baseline were 14.4 (interquartile range, 6.3-36.3) and 14.0 (interquartile range, 5.9-27.8), respectively. In linear regression analysis adjusted for demographics and intracerebral hemorrhage characteristics, absolute leukocyte count was not associated with PHE growth (β, 0.07; standard error, 0.15; P=0.09). In secondary analyses, neutrophil-lymphocyte ratio was correlated with PHE growth (β, 0.22; standard error, 0.08; P=0.005). Conclusions-Higher neutrophil-lymphocyte ratio is independently associated with PHE growth. This suggests that PHE growth can be predicted using differential leukocyte counts on admission.
P erihematomal edema (PHE) is considered a radiological surrogate for secondary injury and inflammation and is independently associated with mortality and poor functional outcomes in intracerebral hemorrhage (ICH) patients. 1 In clinical studies, peripheral blood leukocyte count has been used as a marker for central nervous system inflammation. Absolute and differential leukocyte counts (such as monocyte count and neutrophil-lymphocyte ratio [NLR] ) have been correlated with hematoma expansion and mortality after ICH. 2, 3 Although PHE is believed to be orchestrated by inflammatory pathways, a similar association between PHE and leukocyte count is yet to be elucidated in clinical studies. With ongoing clinical trials in ICH targeting secondary injury, 4 it is important to identify patients at risk for PHE growth early on. Therefore, we aimed to assess the relationship between serum leukocyte counts and PHE growth.
Methods
We performed a retrospective cohort study of ICH patients from the CAESAR registry (cornell acute stroke academic registry) from January 2011 to December 2015. We included all ICH patients >18 years of age, who had noncontrast computed tomographic scans performed on admission and at 24 hours. We excluded patients with secondary causes of ICH (ie, trauma, aneurysms, tumors, and arteriovenous malformations), surgical hematoma evacuation, and conditions with associated leukocytosis, such as infection (in the first week) and hematologic malignancies. The study was approved by the Institutional Review Board at Weill Cornell Medicine.
We measured hematoma and PHE volumes on the baseline scan and the scan closest in time to 24 hours after baseline. A single investigator (Dr Gusdon) measured hematoma and PHE volumes using semiautomated planimetry with 3-dimensional slicer 5, 6 ( Figure 1 ) detailed in the online-only Data Supplement. This method of PHE determination has excellent interrater reliability. 7 Additionally, the interrater intraclass correlation coefficients were 0.82 (0.75-0.89) between 2 independent readers (Drs Gusdon and Murthy) suggesting excellent agreement. Hematoma expansion was defined as an
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September 2017 increase in the absolute baseline hematoma volume by either 33% or >6 mL during 24 hours. 8 Our predictor variables were absolute leukocyte count, NLR, and monocyte count. The primary outcome measure was PHE growth, defined as the difference in the absolute PHE volumes on computed tomography between the 24 hours and baseline studies as used in prior studies. 9 
Statistical Analysis
Continuous variables were represented as median (interquartile range) because they were not normally distributed. We first performed univariable linear regression to identify variables associated with PHE growth, with the threshold of significance set at P<0.20 (Table I in the online-only Data Supplement). Natural logarithmic transformations were performed to minimize skewness of continuous variables when necessary. These covariates were then included in a multiple linear regression to assess the relationship of complete and differential leukocyte counts with PHE growth. The variance inflation factor was used to detect multicollinearity. Sensitivity analyses were performed based on (1) presence of seizures, which can cause leukocytosis; (2) external ventriculostomy drain use because drainage of cerebrospinal fluid can potentially decrease PHE evolution; and (3) inpatient mortality. Statistical analyses were performed using Stata (version 14.0; College Station, TX). All analyses were 2-tailed, and significance level was determined by P<0.05.
Results
A total of 153 patients with ICH were included. Median PHE growth during 24 hours was 3.1 mL (interquartile range, 5.4-27.9; Table 1 ). We built 3 different linear regression models to study the absolute and differential components of the leukocyte count separately. Model covariates included age, baseline hematoma volume, intraventricular extension, external ventriculostomy drain use, Glasgow coma scale, and times to baseline and 24-hour computed tomographic scans ( Table 2 ). The absolute leukocyte count was not significantly correlated with PHE growth (β, 0.07; standard error, 0.15; P=0.09). There was a 22% increase in 24-hour PHE growth per unit increase in NLR (β, 0.22; standard error, 0.08; P=0.005). In sensitivity analyses stratified by presence of seizures in the first 24 hours, external ventriculostomy drain placement and inpatient mortality, NLR remained significantly associated with PHE growth (Table II in the online-only Data Supplement).
Discussion
In this retrospective cohort study at a tertiary-care stroke center, we found baseline NLR to be independently correlated with 24-hour PHE growth after ICH. The inflammatory response after ICH is well known to result in peripheral leukocytosis. 10 ICH leads to microglial activation within hours, which in turn secrete cytokines and chemokines that promote neutrophil and monocyte infiltration within 12 hours. 11 Additionally, recent evidence also suggests that astrocytes shed extracellular vesicles which regulate peripheral leukocyte response in response to brain inflammation. 12 Because inflammation is mainly responsible for PHE evolution, 4 we think peripheral leukocyte count may aid in stratifying the risk of PHE growth at the time of presentation.
Our study has some noteworthy limitations. First, the generalizability of our results may be limited by selection biases, small sample size, and the retrospective nature of this analysis. Second, exclusion of patients who underwent surgical evacuation limits our results to only medically managed ICH patients. Third, we assessed PHE only up to the first 24 hours, whereas it is known that PHE evolves well beyond this time frame. 13 Finally, we also did not have information on body temperature and osmotherapy, both being known predictors of PHE growth. 4 In conclusion, our study demonstrates that baseline NLR is significantly associated with PHE growth in the first 24 hours, suggesting a potential role of inflammatory pathways in the evolution of PHE. Whereas these inflammatory pathways may be potential therapeutic targets, larger prospective studies using additional time points of PHE assessment are required to confirm the role of leukocytes in PHE growth.
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